The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.
Open accessAbstract
A population survey of 258 unrelated white British subjects showed a polymorphism for the 4-oxidation of debrisoquine. "Extensive metabolisers" (EM) and "poor metabolisers" (PM) are recognisable, 8.9% of the population being PM. Nine pedigrees ascertained through PM probands show that the PM phenotype is an autosomal Mendelian recessive character. The EM phenotype is dominant and the degree of dominance has been estimated at 30%. PM subjects are more prone to hypotension during debrisoquine therapy. The alleles controlling this polymorphism appear to control the oxidation of other drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN
Mahgoub, A., Dring, L. G., Idle, J. R., Lancaster, R., & Smith, R. L. (1977) · The Lancet · doi:10.1016/s0140-6736(77)91430-1 · Cited by 1,183
Self-citationDiscombe, G. (1974) · The Lancet · doi:10.1016/s0140-6736(74)91898-4 · Cited by 376
Methodology in medical genetics
Emery, A. E. H. (1976) · Cited by 266
Polymorphism of carbon oxidation of drugs and clinical implications.
Sloan, T. P., Mahgoub, A., Lancaster, R., Idle, J. R., & Smith, R. L. (1978) · BMJ · doi:10.1136/bmj.2.6138.655 · Cited by 116
Self-citationMethodology in Medical Genetics
Carter, C. O. (1976) · BMJ · doi:10.1136/bmj.2.6046.1266-c · Cited by 110
Cited by
The Human Hepatic Cytochromes P450 Involved in Drug Metabolism
Wrighton, S. A., & Stevens, J. C. (1992) · Critical Reviews in Toxicology · doi:10.3109/10408449209145319 · Cited by 944
Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance: Part I
Zhou, S.-F. (2009) · Clinical Pharmacokinetics · doi:10.2165/11318030-000000000-00000 · Cited by 756
Smith, H. S. (2009) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60750-7 · Cited by 696
Newer antidepressants and the cytochrome P450 system
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.3.311 · Cited by 482
Manchikanti, L. (2008) · Pain Physician · doi:10.36076/ppj.2008/11/s5 · Cited by 436
Bertilsson, L. (1995) · Clinical Pharmacokinetics · doi:10.2165/00003088-199529030-00005 · Cited by 432
Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease
Smith, C. A. D., Wolf, C. R., Gough, A. C., Spurr, N. K., Leigh, P. N., Summers, B. A., Harding, A. E., Maranganore, D. M., Sturman, S. G., Williams, A. C., et al. (1992) · The Lancet · doi:10.1016/0140-6736(92)91196-f · Cited by 417
Metabolic oxidation phenotypes as markers for susceptibility to lung cancer
Ayesh, R., Idle, J. R., Ritchie, J. C., Crothers, M. J., & Hetzel, M. R. (1984) · Nature · doi:10.1038/312169a0 · Cited by 383
Self-citationPurification and characterization of hepatic microsomal cytochrome P-450
Ryan, D. E., & Levin, W. (1990) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(90)90029-2 · Cited by 377
The genetic polymorphism of debrisoquine/sparteine metabolism — Clinical aspects
Eichelbaum, M., & Gross, A. S. (1990) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(90)90025-w · Cited by 368
Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in man
K�pfer, A., & Preisig, R. (1984) · European Journal of Clinical Pharmacology · doi:10.1007/bf00541938 · Cited by 362
Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations
Alv�n, G., Bechtel, P., Iselius, L., & Gundert-Remy, U. (1990) · European Journal of Clinical Pharmacology · doi:10.1007/bf00316090 · Cited by 361
Distlerath, L. M., Reilly, P. E., Martin, M. V., Davis, G. G., Wilkinson, G. R., & Guengerich, F. P. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)39456-5 · Cited by 319
Wormhoudt, L. W., Commandeur, J. N. M., & Vermeulen, N. P. E. (1999) · Critical Reviews in Toxicology · doi:10.1080/10408449991349186 · Cited by 302
Clinical Pharmacokinetics and Metabolism of Chloroquine: Focus on Recent Advancements
Ducharme, J., & Farinotti, R. (1996) · Clinical Pharmacokinetics · doi:10.2165/00003088-199631040-00003 · Cited by 289
10-hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes*
Dalén, P., Dahl, M.-L., Ruiz, M. L. B., Nordin, J., & Bertilsson, L. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90040-6 · Cited by 285
Clinical significance of the sparteine/debrisoquine oxidation polymorphism
Br�sen, K., & Gram, L. F. (1989) · European Journal of Clinical Pharmacology · doi:10.1007/bf00637732 · Cited by 282
Oxidation Phenotype — A Major Determinant of Metoprolol Metabolism and Response
Lennard, M. S., Silas, J. H., Freestone, S., Ramsay, L. E., Tucker, G. T., & Woods, H. F. (1982) · New England Journal of Medicine · doi:10.1056/nejm198212163072505 · Cited by 279
Opioid Guidelines in the Management of Chronic Non-Cancer Pain
Manchikanti, L. (2006) · Pain Physician · doi:10.36076/ppj.2006/9/2 · Cited by 277
Bernard, S., Neville, K. A., Nguyen, A. T., & Flockhart, D. A. (2006) · The Oncologist · doi:10.1634/theoncologist.11-2-126 · Cited by 277
Wedlund, P. J., Aslanian, W. S., McAllister, C. B., Wilkinson, G. R., & Branch, R. A. (1984) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1984.256 · Cited by 263
Kronbach, T., Mathys, D., Gut, J., Catin, T., & Meyer, U. A. (1987) · Analytical Biochemistry · doi:10.1016/0003-2697(87)90006-6 · Cited by 261
CYP2D6 and Clinical Response to Atomoxetine in Children and Adolescents With ADHD
MICHELSON, D., READ, H. A., RUFF, D. D., WITCHER, J., ZHANG, S., & McCRACKEN, J. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000246056.83791.b6 · Cited by 159
Ito, T., Kato, M., Chiba, K., Okazaki, O., & Sugiyama, Y. (2010) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.25.243 · Cited by 23
General Principles of Pharmacokinetics
Preskorn, S. H., & Catterson, M. L. (2004) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-18500-7_2 · Cited by 14
Metadata
- Authors
- Evans, D. A., Mahgoub, A., Sloan, T. P., Idle, J. R., & Smith, R. L.
- Venue
- Journal of Medical Genetics
- Publisher
- BMJ
- Published
- 1980-04
- Volume
- 17
- Issue
- 2
- Pages
- 102-105
- ISSN
- 0022-2593 (ISSN-L)
- 1468-6244
- OpenAlex
- W2107472157
- Cited by
- 536
- References
- 5
- FWCI
- 13.59
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.